---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-069927"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:43:42.316994+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantheus closes $275M acquisition of Evergreen Theragnostics; adds OCTEVY and CDMO capabilities

## Summary
- Closed acquisition of Evergreen Theragnostics for $275M cash upfront ($250M + $25M milestone achieved pre-close).
- Additional contingent milestone payments up to $727.5M remain payable under the Merger Agreement.
- Acquisition adds OCTEVY, a registrational-stage PET imaging agent for neuroendocrine tumors.
- Adds Evergreen's radioligand therapy manufacturing infrastructure and revenue-generating CDMO business.
- CEO Brian Markison: acquisition enhances capabilities across the radiopharmaceutical value chain.

## SEC filing metadata
- accession: 0001193125-25-069927
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/0001193125-25-069927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/d905401d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-069927
- JSON: https://secwatch.observer/filing/0001193125-25-069927.json
- Plain text: https://secwatch.observer/filing/0001193125-25-069927.txt

## Key facts
- M&A Transactions
  Lantheus Holdings, Inc. completed an acquisition involving Evergreen Theragnostics, Inc. for approximately $275 million in cash (closed 2025-04-01).
  - Action: acquisition
  - Counterparty: Evergreen Theragnostics, Inc.
  - Consideration: approximately $275 million in cash
  - Closing: 2025-04-01
  source text: (CDMO) services as well as drug discovery and commercialization of proprietary products. In connection with the closing of the Merger, Lantheus Medical paid approximately $275 million in cash, subject to customary adjustments as set forth in the Merger Agreement, representing the $250 million upfront cash payment and a $25 million milestone payment in respect
  evidence_url: https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/0001193125-25-069927-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.